A patient with HFrEF derives symptomatic benefit from an ACE inhibitor and MRA but develops recurrent potassium 5.7 mmol/L despite correcting diet

Question

A patient with HFrEF derives symptomatic benefit from an ACE inhibitor and MRA but develops recurrent potassium 5.7 mmol/L despite correcting diet and stopping NSAIDs. Which strategy may preserve prognostic therapy?

Accepted Answer

Use a licensed potassium binder with close biochemical monitoring

Answer

Replace the MRA with verapamil

Answer

Permanently withdraw all renin–angiotensin system inhibition

Answer

Accept potassium above 6.0 mmol/L without surveillance

Answer

Add routine potassium supplementation with each diuretic dose

Daily Weight Monitoring in HF — EECC MCQ

A patient with HFrEF derives symptomatic benefit from an ACE inhibitor and MRA but develops recurrent potassium 5.7 mmol/L despite correcting diet and stopping NSAIDs. Which strategy may preserve prognostic therapy?